Boston Scientific Announces FDA Approval For Latest-Generation WATCHMAN FLX Pro Left Atrial Appendage Closure Device
Portfolio Pulse from Benzinga Newsdesk
Boston Scientific has received FDA approval for its latest-generation WATCHMAN FLX Pro Left Atrial Appendage Closure Device. This approval could potentially boost the company's revenues and market share in the medical devices sector.
September 06, 2023 | 8:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
The FDA approval of Boston Scientific's latest-generation WATCHMAN FLX Pro device could potentially increase the company's revenues and market share in the medical devices sector.
FDA approval is a significant milestone for any medical device company. It allows the company to market and sell its product in the US, which can lead to increased revenues and market share. Given that Boston Scientific is a major player in the medical devices sector, this approval could have a significant positive impact on its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100